The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Interleukin-6 in rheumatoid arthritis
Abstract
PURPOSE OF REVIEW: Recent progress in cytokine studies has clarified the pathological roles played by cytokines and provided key evidence that antagonizing their actions can be therapeutic. The pathogenesis of rheumatoid arthritis, an autoimmune inflammatory disease, involves inflammatory cytokines such as tumour necrosis factor-alpha, interleukin-1 and interleukin-6. Anti-tumour necrosis factor-alpha and anti-interleukin-1 therapies have been used successfully to treat rheumatoid arthritis, but they are not consistently effective. We therefore need further therapies for this refractory disease. Interleukin-6 is another target molecule for blockade in the treatment of rheumatoid arthritis. Tocilizumab is a humanized antihuman interleukin-6 receptor monoclonal antibody designed to block the actions of interleukin-6. This review addresses the pathological significance of interleukin-6 and the current status of anti-interleukin-6 therapy for rheumatoid arthritis. RECENT FINDINGS: The safety and efficacy of tocilizumab have been demonstrated in clinical trials conducted in patients with rheumatoid arthritis and other autoimmune inflammatory diseases, such as juvenile idiopathic arthritis and Crohn's disease. SUMMARY: Clinical studies have demonstrated the pathological significance of interleukin-6 and the safety and efficacy of anti-interleukin-6 therapy with tocilizumab. Blockade of interleukin-6 - the second generation of anticytokine therapy - may be a promising treatment for rheumatoid arthritis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Houssiau, F. A., Devogelaer, J., Damme, J. V., Deuxchaisnes, C. N. D., & Snick, J. V. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310614 · Cited by 847
Ito, H., Takazoe, M., Fukuda, Y., Hibi, T., Kusugami, K., Andoh, A., Matsumoto, T., Yamamura, T., Azuma, J., & Nishimoto, N. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.012 · Cited by 636
Self-citationChoy, E. H. S., Isenberg, D. A., Garrood, T., Farrow, S., Ioannou, Y., Bird, H., Cheung, N., Williams, B., Hazleman, B., Price, R., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10623 · Cited by 526
Self-citationMadhok, R., Crilly, A., Watson, J., & Capell, H. A. (1993) · Annals of the Rheumatic Diseases · doi:10.1136/ard.52.3.232 · Cited by 340
Atsumi, T., Ishihara, K., Kamimura, D., Ikushima, H., Ohtani, T., Hirota, S., Kobayashi, H., Park, S.-J., Saeki, Y., Kitamura, Y., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020619 · Cited by 225
Cited by
Nishimoto, N., Hashimoto, J., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Murata, N., van der Heijde, D., & Kishimoto, T. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.068064 · Cited by 727
Self-citationThe role of inflammation in the development of epilepsy
Rana, A., & Musto, A. E. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1192-7 · Cited by 709
Kisacik, B., Tufan, A., Kalyoncu, U., Karadag, O., Akdogan, A., Ozturk, M. A., Kiraz, S., Ertenli, I., & Calguneri, M. (2008) · Joint Bone Spine · doi:10.1016/j.jbspin.2007.06.016 · Cited by 421
The IL-23/Th17 axis: therapeutic targets for autoimmune inflammation
Kikly, K., Liu, L., Na, S., & Sedgwick, J. D. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.09.008 · Cited by 303
Suppression of adjuvant arthritis by hesperidin in rats and its mechanisms
Li, R., Li, J., Cai, L., Hu, C.-M., & Zhang, L. (2008) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.60.2.0011 · Cited by 84
Metadata
- Authors
- Nishimoto, N.
- Venue
- Current Opinion in Rheumatology
- Published
- 2006-05
- Volume
- 18
- Issue
- 3
- Pages
- 277-281
- ISSN
- 1040-8711 (ISSN-L)
- OpenAlex
- W2056820322
- Cited by
- 184
- References
- 5
- FWCI
- 8.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interleukin-6 in rheumatoid arthritis. https://app.cochat.ai/papers/10.1097/01.bor.0000218949.19860.d1
- The paper
- Nishimoto, N. (2006). Interleukin-6 in rheumatoid arthritis. Current Opinion in Rheumatology. https://doi.org/10.1097/01.bor.0000218949.19860.d1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.